Raf, thank you for posing the issues in such a clear fashion.
From a litigator's point of view, the clear-cut case would be if the generic was not the bioequivalent of the real Vascepa, specifically, a clinically and medically inferior knock-off. From what you say, that appears not to be the case.
Yet it is interesting and baffling to me as to how it can be the bioequivalent, yet give off the rotten fish odor, unless the answer lies in the composition of the capsule.
Note that the product could meet FDA standards but still violate consumer fraud laws, if the generic manufacturer omits material facts about the product from consumers, where knowledge of those facts would affect the consumer's decision to use the product.
Market Data 
Markets 
AI
